Abstract

Although Alzheimer’s disease (AD) causes massive and irreversible neurodegeneration, prevention and curing early stages of the disease appears to represent a realistic goal to be achieved in future. In fact, one of the very first effective treatments available could be derived from ordinary food sources.Overproduction of the amyloidogenic peptide Aβ42 causes AD. Thus far two physiological regulatory cycles were identified in which Aβ peptides play a major role. These regulatory cycles are involved in cholesterol and sphingolipid homeostasis. Moreover, Aβ production is under physiological conditions tightly regulated and its production rate is highly sensitive to alterations of the cellular membrane composition. Several lipids, sterols and fatty acids have thus far been identified to affect Aβ production. Most knowledge thus far has been gathered about those lipids which are themselves are target of Aβ mediated lipid homeostasis, cholesterol and sphingomyelin. E.g. cholesterol strongly increases Aβ production and cholesterol lowering with statins is a matter of intense clinical research not only for cardiovascular disease preventions but now also for AD therapy. Special interest received n-3 polyunsaturated fatty acids, especially DHA, because of their Aβ lowering effect in combination with favorable pharmacokinetics and neuroprotective properties.

Highlights

  • When Alois Alzheimer a century ago identified amyloid plaques as the hallmark and molecular manifestation of dementia in the elderly, he set the stage for what has become a major scientific effort – treating and preventing Alzheimer’s disease (AD)

  • Until recently little indication existed for a link between AD, Amyloid Precursor Protein (APP) processing and cholesterol homeostasis

  • First indications that lipids may play an important role in APP processing and Amyloid beta (Ab) production are given by the finding that all proteins involved in APP processing are integral membrane proteins

Read more

Summary

Introduction

When Alois Alzheimer a century ago identified amyloid plaques as the hallmark and molecular manifestation of dementia in the elderly, he set the stage for what has become a major scientific effort – treating and preventing Alzheimer’s disease (AD). Especially concerning cholesterol, have recently been discovered to be very closely linked This linkage has been observed on all levels of research. Until recently little indication existed for a link between AD, Amyloid Precursor Protein (APP) processing and cholesterol homeostasis. This picture has changed dramatically over the last years. It is clear that the Ab generating machinery is an integral part of the body’s lipid homeostasis regulating system which causes it to respond very sensitively to changes in lipid levels [15] It is becoming ever more evident, that there are several more routes through which lipids can have either a beneficial or a detrimental impact on the brain. The n3-fatty acids docosahexaenic acid (DHA) and eicosapentaenoic acid (EPA) represent promising candidate and a first clinical trial ended with positive results

Disease etiology
Mechanistic lipid link
Findings
Clinical perspective
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call